Effect of omega-3 fatty acid ethyl esters on the oxylipin composition of lipoproteins in hypertriglyceridemic, statin-treated subjects

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Newman, John W ^a,b   Pedersen, Theresa L ^a   Brandenburg, Verdayne R ^c   Harris, William S ^c   Shearer, Gregory C ^c,d,e  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

^d SANFORD RESEARCH   (United States)

^e PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11,12 DIHYDROXY EICOSATRIENOIC ACID; 12 HYDROXY EICOSAPENTAENOIC ACID; 12 HYDROXYICOSATETRAENOIC ACID; 14 (15)EPOXYEICOSATETRAENOIC ACID; 14,15 DIHYDROXY EICOSATRIENOIC ACID; 14,15 HYDROXYEICOSATETRAENOIC ACID; 15 HYDROXY EICOSAPENTAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 17 (18)EPOXYEICOSATETRAENOIC ACID; 17 HYDROXY DOCOSAHEXAENOIC ACID; 17,18 HYDROXYEICOSATETRAENOIC ACID; 19,20 DOCOSAHEXAENOIC ACID; 5 HYDROXY EICOSAPENTAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; 8,9 EPOXYICOSATRIENOIC ACID; 9 HYDROXYICOSATETRAENOIC ACID; DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; OXYLIPIN; PHOSPHOLIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNSATURATED FATTY ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; ARACHIDONIC ACID; EPOXIDE; HIGH DENSITY LIPOPROTEIN; KETONE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CORRELATIONAL STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; FATTY ACID TRANSPORT; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MALE; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; THERAPY EFFECT; BLOOD; METABOLISM; MIDDLE AGED;

ARACHIDONIC ACID; EPOXY COMPOUNDS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; KETONES; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; OXYLIPINS;

EID: 84911920729     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111471     Document Type: Article

References (42)

1. 2001 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239.
3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, et al. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis.
4. Buczynski MW, Dumlao DS, Dennis EA (2009) Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res 50: 1015-1038.
5. Westphal C, Konkel A, Schunck WH (2011) CYP-eicosanoids-a new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat 96: 99-108.
6. Serhan CN (2002) Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 68-69: 433-455.
7. Mozaffarian D, Wu JH (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58: 2047-2067.
8. Keenan AH, Pedersen TL, Fillaus K, Larson MK, Shearer GC, et al. (2012) Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to highdose n3-HUFA in healthy volunteers. J Lipid Res.
9. Shearer GC, Harris WS, Pedersen TL, Newman JW (2010) Detection of omega- 3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J Lipid Res 51: 2074-2081.
10. Shearer GC, Newman JW (2008) Lipoprotein lipase releases esterified oxylipins from very low-density lipoproteins. Prostaglandins Leukot Essent Fatty Acids 79: 215-222.
11. Newman JW, Kaysen GA, Hammock BD, Shearer GC (2007) Proteinuria increases oxylipid concentrations in VLDL and HDL but not LDL particles in the rat. J Lipid Res 48: 1792-1800.
12. Stenson WF, Parker CW (1979) 12-L-hydroxy-5, 8, 10, 14-eicosatetraenoic acid, a chemotactic fatty acid, is incorporated into neutrophil phospholipids and triglyceride. Prostaglandins 18: 285-292.
13. Fang X, Weintraub NL, Stoll LL, Spector AA (1999) Epoxyeicosatrienoic acids increase intracellular calcium concentration in vascular smooth muscle cells. Hypertension 34: 1242-1246.
14. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, et al. (2007) Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29: 1354-1367.
15. Innis-Whitehouse W, Li X, Brown WV, Le NA (1998) An efficient chromatographic system for lipoprotein fractionation using whole plasma. J Lipid Res 39: 679-690.
16. Shearer GC, Newman JW, Hammock BD, Kaysen GA (2005) Graded effects of proteinuria on HDL structure in nephrotic rats. J Am Soc Nephrol 16: 1309-1319.
17. Shearer GC, Chen J, Chen Y, Harris WS (2009) Myocardial infarction does not affect fatty-acid profiles in rats. Prostaglandins Leukot Essent Fatty Acids 81: 411-416.
18. Gladine C, Newman JW, Durand T, Pedersen TL, Galano JM, et al. (2014) Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention. PLoS One 9: e89393.
19. Mallat Z, Nakamura T, Ohan J, Leseche G, Tedgui A, et al. (1999) The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 103: 421-427.
20. Erlemann KR, Rokach J, Powell WS (2004) Oxidative stress stimulates the synthesis of the eosinophil chemoattractant 5-oxo-6, 8, 11, 14-eicosatetraenoic acid by inflammatory cells. J Biol Chem 279: 40376-40384.
21. Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, et al. (2009) Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 50: 204-213.
22. Zarini S, Gijon MA, Ransome AE, Murphy RC, Sala A (2009) Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation. Proc Natl Acad Sci U S A 106: 8296-8301.
23. Grant GE, Rokach J, Powell WS (2009) 5-Oxo-ETE and the OXE receptor. Prostaglandins Other Lipid Mediat 89: 98-104.
24. Whatling C, McPheat W, Herslof M (2007) The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field. Expert Opin Investig Drugs 16: 1879-1893.
25. Kogure R, Toyama K, Hiyamuta S, Kojima I, Takeda S (2011) 5-Hydroxyeicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucosedependent insulin secretion. Biochem Biophys Res Commun 416: 58-63.
26. Cole BK, Kuhn NS, Green-Mitchell SM, Leone KA, Raab RM, et al. (2012) 12/15-Lipoxygenase signaling in the endoplasmic reticulum stress response. Am J Physiol Endocrinol Metab 302: E654-665.
27. Wittwer J, Hersberger M (2007) The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 77: 67-77.
28. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, et al. (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 102: 9772-9777.
29. Neckar J, Kopkan L, Huskova Z, Kolar F, Papousek F, et al. (2012) Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]- benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci (Lond) 122: 513-525.
30. Larsen BT, Zhang DX, Gutterman DD (2007) Epoxyeicosatrienoic acids, TRP channels, and intracellular Ca2+ in the vasculature: an endothelium-derived endothelium-hyperpolarizing factor? Arterioscler Thromb Vasc Biol 27: 2496-2498.
31. Ye D, Zhang D, Oltman C, Dellsperger K, Lee HC, et al. (2002) Cytochrome p- 450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J Pharmacol Exp Ther 303: 768-776.
32. Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC, et al. (2001) EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. Am J Physiol Heart Circ Physiol 280: H2430-2440.
33. Newman JW, Hammock BD (2001) Optimized thiol derivatizing reagent for the mass spectral analysis of disubstituted epoxy fatty acids. J Chromatogr A 925: 223-240.
34. Lewis TV, Dart AM, Chin-Dusting JP (1999) Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. J Am Coll Cardiol 33: 805-812.
35. Norata GD, Pirillo A, Callegari E, Hamsten A, Catapano AL, et al. (2003) Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Cardiovasc Res 59: 169-180.
36. Prisco D, Paniccia R, Bandinelli B, Filippini M, Francalanci I, et al. (1998) Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res 91: 105-112.
37. Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, et al. (2000) Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 102: 1264-1269.
38. Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ (2000) Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 35: 265-270.
39. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, et al. (2003) Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A 100: 2730-2735.
40. Ruby MA, Goldenson B, Orasanu G, Johnston TP, Plutzky J, et al. (2010) VLDL hydrolysis by LPL activates PPAR-alpha through generation of unbound fatty acids. J Lipid Res 51: 2275-2281.
41. Brown JD, Oligino E, Rader DJ, Saghatelian A, Plutzky J (2011) VLDL hydrolysis by hepatic lipase regulates PPARdelta transcriptional responses. PLoS One 6: e21209.
42. Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, et al. (2006) Highdensity lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res 98: 490-498.